Stocks · News reference
Filed: 2026-10-14 AccNo: 0001104659-26-115874 Size: 214 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Rezolute, Inc. (NASDAQ:RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that the open-label
Analysts upgraded NetApp, Humana, Corteva, Afya, with price-target changes for four stocks.
Lake Street analyst Daniel Brims maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $9 to $12.